Drug-induced lupus erythematosus

Cutaneous Lupus Erythematosus

Volumn , Issue , 2005, Pages 117-132

  Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149149703     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-26581-3_9     Document Type: Chapter

References (95)

1. Adams LE, Hess EV (1991) Drug-related lupus. Drug Safety 6:431-449
2. Alarcon-Segovia D, Fishbein E, Reyes PA, Dies H, Shwadsky S (1972) Antinuclear antibodies in patients on anticonvulsant therapy. Clin Exp Immunol 12:39-47
3. Alloway JA, Salata MP (1995) Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum 24:315-322
4. Amrhein JA, Kenny FM, Ross D (1970) Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J Pediatr 76:54-63
5. Aucoin DP, Peterson ME, Hurvitz AI, Drayer DE, Lahita RG, Quimby FW, Reidenberg M M (1985) Propylthiouracil-induced immune-mediated disease in the cat. J Pharmacol Exp Ther 234:13-18
6. Aucoin DP, Rubin RL, Peterson ME, Reidenberg MM, Drayer DE, Hurvitz AI, Lahita RG (1988) Dose-dependent induction of anti-native DNA antibodies in cats bypropylthiouracil. Arthritis Rheum 31:688-692
7. Batchelor JR, Welsh KI, Tinoco RM, Dollery CT, Hughes GR, Bernstein R, Ryan P, Naish PF, Aber GM, Bing RF, Russel GI 1980 Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1:1107-1109
8. Beernink DH, Miller JJ (1973) Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children. J Pediatr 82:113-117
9. Blomgren SE, Condemi JJ, Vaughn JH (1972) Procainamide-induced lupus erythematosus: clinical and laboratory observations. Am J Med 52:338-348
10. Booth RJ, Wilson JD, Bullock JY (1982) β-Adrenergic-receptor blockers and antinuclear antibodies in hypertension. Clin Pharmacol Ther 31:555-558
11. Brand C, Davidson A, Littlejohn G, Ryan P (1984) Hydralazine-induced lupus: no association with HLA-DR4. Lancet 1:462
12. Burlingame RW, Rubin RL (1991) Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 88:680-690
13. Cameron HA, Ramsay LE (1984) The lupus syndrome induced by hydralazine: a common complication with low dose therapy. Br Med J 289:410-412
14. Canoso R, Lewis M, Yunis E (1982) Association of HLA-Bw44 with chlorpromazine-induced autoantibodies. Clin Immunol Immunopathol 25:278-282
15. CAST (1989) Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412
16. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383-2390
17. Chin G, Kong N, Lee B, Rose I (1991) Penicillamine induced lupus-like syndrome in a patient with classical rheumatoid arthritis. J Rheumatol 18:947-948
18. Christie DJ, Mullen PC, Aster RH (1985) Fab-mediated binding of drug-dependent antibodies to platelets in quinidine-and quinine-induced thrombocytopenia. J Clin Invest 75:310-314
19. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B (1988) Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140:2197-2200
20. Derksen R, Kater L (1985) Lupus anticoagulant: revival of an old phenomenon. Clin Exp Rheumatol 3:349-357
21. Donker AJ, Venuto RC, Vladutiu AO, Brentjens JR, Andres GA (1984) Effects of prolonged administration of D-penicillamine or captopril in various strains of rats. Clin Immunol Immunopath 30:142-155
22. Dubois EL, Wallace DJ (1987) Drugs that exacerbate and induce systemic lupus erythematosus In: Wallace DJ, Dubois EL (eds) Dubois' Lupus Erythematosus. Lea & Febiger, Philadelphia, pp 450-469
23. Dubois EL, Tallman E, Wonka RA (1972) Chlorpromazine-induced systemic lupus erythematosus: case report and review of the literature. J Am Med Assoc 221:595-596
24. Dubroff LM, Reid R Jr, Papalian M (1981) Molecular models for hydralazine-related systemic lupus erythematosus. Arthritis Rheum 24:1082-1085
25. Dunphy J, Oliver M, Rands AL, Lovell CR, McHugh NJ (2000) Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 142:461-467
26. Falk RJ, Terrell RS, Charles LA, Jennette JC (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115-4119
27. Fritzler MJ, Tan EM (1978) Antibodies to histones in drug-induced and idiopathic lupus erythematosus. J Clin Invest 62:560-567
28. Fukuyama S, Kajiwara E, Suzuki N, Miyazaki N, Sadoshima S, Onoyama K (2000) Systemic lupus erythematosus after alpha-interferon therapy for chronic hepatitis C: a case report and review of the literature. Am J Gastroenterol 95:310-312
29. Ghate J, Turner M, Rudek M, Figg W, Dahut W, Dyer V, Pluda J, Reed E (2001) Drug-induced lupus associated with COL-3: report of 3 cases. Arch Dermatol 137:471-474
30. Gleichmann E, Pals WT, Rolink AG, Radaszkiewicz T, Gleichmann H (1984) Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 5:324-332
31. Gleichmann H (1982) Systemic lupus erythematosus triggered by diphenylhydantoin. Arthritis Rheum 25:1387-1388
32. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS (1991) Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 18:1621-1622
33. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E (1998) Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 19:133-141
34. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B (1997) Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 36:1089-1094
35. Hahn BH, Sharp GC, Irvin WS, Kantor OS, Gardner CA, Bagby MK, Perry HM Jr, Osterland CK (1972) Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus. Ann Intern Med 76:365-374
36. Harkcom TM, Conn DL, Holley KE (1978) D-Penicillamine and lupus erythematosus-like syndrome. Ann Intern Med 89:1012
37. Henningsen NC, Cederberg A, Hanson A, Johansson BW (1975) Effects of long-term treatment with procaine amide. Acta Med Scand 198:475-482
38. Hieronymus T, Grotsch P, Blank N, Grunke M, Capraru D, Geiler T, Winkler S, Kalden JR, Lorenz HM (2000) Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? Arthritis Rheum 43:1994-2004
39. Hoffman BJ (1945) Sensitivity to sulfadiazine resembling acute lupus erythematosus. Arch Dermatol Syph 51:190-192
40. Hofstra A, Uetrecht JP (1993) Metabolism of hydralazine to a reactive intermediate by the oxidizing system of activated leukocytes. Chem Biol Interact 89:183-196
41. Jaffe IA (1981) Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases. Springer Semin Immunopathol 4:193-207
42. Jain KK (1991) Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy. Drug Saf 6:350-360
43. Ju C, Uetrecht JP (1999) Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J Pharmacol Exp Ther 288:51-56
44. Kalyanaraman B, Sohnle PG (1985) Generation of free radical intermediates from foreign compounds by neutrophil-derived oxidants. J Clin Invest 75:1618-1622
45. Kammuller ME, Bloksma N, Seinen W (1988) Chemical-induced autoimmune reactions and Spanish toxic oil syndrome. Focus on hydantoins and related compounds. J Toxicol Clin Toxicol 26:157-174
46. + mice. Toxicol Appl Pharmacol 134:155-160
47. Kilburn KH, Warshaw RH (1992) Prevalence of symptoms of systemic lupus erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure to trichloroethylene and other chemicals in well water. Environ Res 57:1-9
48. Knezevic W, Mastaglia FL, Quintner J, Zilko PJ (1984) Guillain-Barre syndrome and pemphigus foliaceus associated with D-penicillamine therapy. Aust NZ J Med 14:50-52
49. Kretz-Rommel A, Duncan SR, Rubin RL (1997) Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus. J Clin Invest 99:1888-1896
50. Kretz-Rommel A, Rubin RL (1999) Persistence of autoreactive T cell drive is required to elicit anti-chromatin antibodies in a murine model of drug-induced lupus. J Immunol 162:813-820
51. Laversuch CJ, Collins DA, Charles PJ, Bourke BE (1995) Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease. Br J Rheumatol 34:435-439
52. Lawson TM, Amos N, Bulgen D, Williams BD (2001) Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 40:329-335
53. Lee SL, Chase PH (1975) Drug-induced systemic lupus erythematosus: a critical review. Semin Arthritis Rheum 5:83-103
54. Lessard E, Fortin A, Belanger PM, Beaune P, Hamelin BA, Turgeon J (1997) Role of CYP2D6 in the N-hydroxylation of procainamide. Pharmacogenetics 7:381-390
55. Machold KP, Smolen JS (1990) Interferon-gamma induced exacerbation of systemic lupus erythematosus. J Rheumatol 17:831-832
56. Mackie BS, Mackie LE (1999) The PABA story. Australas J Dermatol 40:51-53
57. Maddrey WC, Boitnott JK (1973) Isoniazid hepatitis. Ann Intern Med 79:1-12
58. Malinow MR, Bardana EJ, Pirofsky B, Craig S, McLaughlin P (1982) Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: role of a nonprotein amino acid. Science 216:415-417
59. Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59:1341-1359
60. Matsuura T, Shimizu Y, Fujimoto H, Miyazaki T, Kano S (1992) Minocycline-related lupus. Lancet 340:1553
61. Nassberger L, Sjoholm AG, Jonsson H, Sturfelt G, Akesson A (1990) Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 81:380-383
62. Perry HM (1973) Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 54:58-72
63. Perry HM, Tan EM, Cordody S, Sahamato A (1970) Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms on hypertensive patients treated with hydralazine. J Lab Clin Med 76:114-125
64. Portanova JP, Arndt RE, Tan EM, Kotzin BL (1987) Anti-histone antibodies in idiopathic and drug-induced lupus recognize distinct intrahistone regions. J Immunol 138:446-451
65. Price EJ, Venables PJ (1995) Drug-induced lupus. Drug Saf 12:283-290
66. Raftery EB, Denman AM (1973) Systemic lupus erythematosus syndrome induced by practolol. Br Med J 2:452-455
67. Reidenberg MM (1983) Aromatic amines and the pathogenesis of lupus erythematosus. Am J Med 75:1037-1042
68. Reidenberg MM, Durant PJ, Harris RA, De Boccardo G, Lahita R, Stenzel KH (1983) Lupus erythematosus-like disease due to hydrazine. Am J Med 75:365-370
69. Reza MJ, Dornfeld L, Goldberg LS (1975) Hydralazine therapy in hypertensive patients with idiopathic systemic lupus erythematosus. Arthritis Rheum 18:335-338
70. Rich MW (1996) Drug-induced lupus: the list of culprits grows. Postgrad Med 100:299-308
71. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M (1990) Evidence for impaired T cell methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33:1665-1673
72. Ronnblom LE, Alm GV, Oberg KE (1990) Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 227:207-210
73. Rothfield NF, Bierer WF, Garfield JW (1978) Isoniazid induction of antinuclear antibodies: a prospective study. Ann Intern Med 88:650-652
74. Rutgeerts P, D'Haens G, Targan S, Vasiliaskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ 1999 Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761-769
75. Schaffer JV, Davidson DM, McNiff JM, Bolognia JL (2001) Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J Am Acad Dermatol 44:198-206
76. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M (1991) Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 68:1536-1537
77. Shapiro KS, Pinn VW, Harrington JT, Levey AS (1984) Immune complex glomerulnephritis in hydralazine-induced SLE. Am J Kidney Dis 3:270-274
78. Shapiro LE, Knowles SR, Shear NH (1997) Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 133:1224-1230
79. Shapiro LE, Uetrecht J, Shear NH (2001) Minocycline, perinuclear antineutrophilic cytoplasmic antibody, and pigment: the biochemical basis. J Am Acad Dermatol 45:787-789
80. Shear NH, Spielberg SP (1988) Anticonvulsant hypersensitivity syndrome. J Clin Invest 82:1826-1832
81. Sim E, Law SA (1985) Hydralazine binds covalently to complement component C4: different reactivity of C4A and C4B gene products. FEBS 184:323-327
82. Sim E, Stanley L, Gill EW, Jones A (1988) Metabolites of procainamide and practolol inhibit complement components C3 and C4. Biochem J 251:323-326
83. Spielberg SP, Gordon GB, Blake DA, Mellits ED, Bross DS (1981) Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 217:386-389
84. Stec GP, Lertora J J L, Atkinson AJ, Nevin MJ, Kushner W, Jones C, Schmid FR, Askenazi J (1979) Remission of procainamide-induced lupus erythematosus with N-acetylprocainamide therapy. Ann Intern Med 90:799-801
85. Steinberg AD, Gourley MF, Klinman DM, Tsokos GC, Scott DE, Krieg AM (1991) NIH conference. Systemic lupus erythematosus. Ann Intern Med 115:548-559
86. Tournade H, Pelletier L, Pasquier R, Vial M, Mandet C, Druet P (1990) D-Penicillamine-induced autoimmunity in Brown-Norway rats: similarities with HgCl2-Induced autoimmunity. J Immunol 144:2985-29912
87. Uetrecht JP (1988) Mechanism of drug-induced lupus. Chem Res Toxicol 1:133-143
88. Uetrecht JP (1996) Drug-induced lupus: possible mechanisms and their implications for prediction of which new drugs may induce lupus. Expert Opinion on Invest Drugs 5:851-860
89. Uetrecht JP, Woosley RL (1981) Acetylator phenotype and lupus erythematosus. Clin Pharmacokin 6:118-134
90. Waldhauser L, Uetrecht J (1991) Oxidation of propylthiouracil to reactive metabolites by activated neutrophils: implications for agranulocytosis. Drug Metab Dispos 19:354-359
91. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317
92. Wilson JD, Bullock JY, Sutherland DC, Main C, O'Brien KP (1978) Antinuclear antibodies in patients receiving non-practolol beta-blockers. Br Med J 1:14-16
93. Woosley RL, Drayer DE, Reidenberg MM, Nies AS, Carr K, Oates JA (1978) Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 298:1157-1159
94. Yung RL, Richardson BC (1994) Drug-induced lupus. Rheum Dis Clin North Am 20:61-86
95. Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, Varma AO (1979) Imunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 91:194-199.